New weight loss drug IBIO-600 enters first human trial

NCT ID NCT07487376

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a single dose of the experimental drug IBIO-600 in 32 overweight or obese adults. The main goal is to see if the drug is safe and tolerable, and to measure how it moves through the body. Researchers will also look at its effect on body composition. This is a first step toward possibly developing a new weight management treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

IBIO-600

What this could lead to

If it works, this could point toward a new treatment for weight management in people who are overweight or obese.

What could go wrong

This is a very early Phase 1 trial with only 32 participants, so it's primarily checking safety, not effectiveness. The drug may not lead to meaningful weight loss or could have side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT , OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Veritus Research

    RECRUITING

    Bayswater, Victoria, 3153, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••